rituximab,ibrutinib,Bendamustine
biogen,roche,novartis,janssen,abbvie
['shine', 'lymphoma']
 presenting the phase iii shine trial comparing ibrutinib + br vs. br in #mcl as 1st line in elderly pts. 2.3 yr pfs benefit in ibrutinib + br arm. no os benefit yet. new bench mark for mcl rx in this population. #lymphoma #asco22 
Assist-Prof of Med, @MayoClinic FL, #ASCOTEC, ASCO AMEC. #Lymphoma #PTCL #CTCL #histiocyticDiseases #ClinicalResearch ?????? ????? ?? ?????? #???????